Federal Register #FDA2026N10232

FDA Public Advisory Committee Meeting on Influenza Vaccine Strain Selection – Request for Public Comments

The Food and Drug Administration (FDA), under the Department of Health and Human Services, is announcing a public advisory committee meeting regarding influenza vaccine strain selection for the 2027 Southern Hemisphere season. - Government Buyer: - Department of Health and Human Services - Food and Drug Administration (FDA) - Vaccines and Related Biological Products Advisory Committee - OEMs and Vendors: - No OEMs or vendors are mentioned; this is not a procurement opportunity - Products/Services Requested: - No products or services are being requested or procured - Unique or Notable Requirements: - Public comments are solicited via an established docket (FDA-2026-N-10232) - The meeting is open to the public and will be held virtually - Opportunities for oral and written presentations are available - Information about the National Vaccine Injury Compensation Program and recent petitions is included - No procurement activity, contract, or solicitation for goods/services is present in this notice

Description

The Food and Drug Administration (FDA) announces a public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee to discuss strain selection for influenza virus vaccines for the 2027 Southern Hemisphere influenza season. The meeting will be held virtually on October 1, 2026, from 9:00 a.m. to 1:00 p.m. Eastern Time. The FDA is establishing a public docket for comments related to the meeting, which will close on September 29, 2026. Interested persons may present data, information, or views orally or in writing, and the meeting will be accessible via online teleconferencing and video conferencing platforms.

View original listing